U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi): CADTH Reimbursement Recommendation: Indication: For the first-line treatment of adult patients with unresectable hepatocellular carcinoma who require systemic therapy [Internet].

Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi): CADTH Reimbursement Recommendation: Indication: For the first-line treatment of adult patients with unresectable hepatocellular carcinoma who require systemic therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...